CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform

On February 2, 2026 CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo CAR therapy, reported new detailed data demonstrating complete B cell depletion in NHPs using its proprietary in vivo CAR-T platform. The results will be presented at the Keystone Symposia: Emerging Cell Therapies conference, held February 1-4 in Banff, Alberta.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The broad potential of our platform across oncology and autoimmune is now validated in both humans and NHPs," said Robert Hofmeister, PhD, Chief Scientific Officer of CREATE Medicines. "This represents a major leap in the field of in vivo CAR therapies, demonstrating that targeted T cell programming is not only possible, but redosable and clinically de-risked with our platform."

Key Highlights:

Complete B cell depletion in NHPs using both a next-generation T cell receptor-specific CAR and a conventional 41BBζ CAR.
Validated RNA-LNP delivery system capable of modular CAR deployment and targeted immune cell programming in vivo.
Flexible receptor architecture enabling tailored immune activation, persistence, and control across indications.
CREATE’s in vivo CAR-T platform is designed to overcome key limitations of ex vivo cell therapies, removing the need for cell harvesting, manipulation, or conditioning regimens. CREATE’s platform also enables the use of CARs that integrate into the T cell receptor, a feature lacking in currently used approaches, allowing precise immune cell programming without off-target expression. This modularity is central to CREATE’s multi-immune programs, where selective functionality and control are critical.

Presentation Details

Keystone Symposia: Emerging Cell Therapies

Time: Monday, February 2: 7:30 p.m. MST
Location: Fairmont Banff Springs, Banff, AB, Canada
Poster Number: 1533
Poster Title: In Vivo Generation of CAR-T Cells for the Treatment of B Cell Mediated Autoimmunity and Hematological Malignancies
Meeting program: View Source

(Press release, Create Medicines, FEB 2, 2026, View Source [SID1234662404])